Clinical Trials Logo

Chronic Hepatitis C (CHC) clinical trials

View clinical trials related to Chronic Hepatitis C (CHC).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03868163 Completed - Clinical trials for Chronic Hepatitis C (CHC)

Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation

EVEREST
Start date: February 28, 2019
Phase:
Study type: Observational

This study seeks to assess the effectiveness of Glecaprevir plus Pibrentasvir in participants with chronic hepatitis C in a real-life setting across clinical practice populations in the Russian Federation.

NCT ID: NCT01753570 Completed - Clinical trials for Chronic Hepatitis C(CHC)

Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

Start date: December 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of MP-424 with IFN beta and RBV in patients with genotype 1/2 hepatitis C, who are treatment-naïve or have received its treatment before.

NCT ID: NCT01753557 Completed - Clinical trials for Chronic Hepatitis C (CHC)

Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C

Start date: December 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of MP-424 with PEG-IFN Alfa-2a and RBV in patients with genotype 1 hepatitis C, who are naïve to its treatment or relapsed after previous treatment.

NCT ID: NCT01710501 Completed - Clinical trials for Chronic Hepatitis C (CHC)

A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)

Start date: December 7, 2012
Phase: Phase 2
Study type: Interventional

This is a study designed to compare the safety and efficacy of 3 different doses of grazoprevir (MK-5172) combined with pegylated interferon alfa-2b (PEG-IFN) and ribavirin (RBV) in treatment-naïve participants with genotype 1 (GT1) chronic hepatitis C (CHC). Participants will receive 12 weeks of treatment with grazoprevir combined with Peg-IFN and RBV, and depending on response at Week 4 may go on to receive an additional 12 weeks of treatment with Peg-IFN and RBV.